New NCCN Guidelines Stress Genetic Testing For All Pancreatic Cancer Patients
Dr. Sapna Syngal discusses the new NCCN guidelines, which support genetic testing for all pancreatic cancer patients, because mutations can influence treatment.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
But newer approaches like targeted therapies take aim at very specific genetic changes and the proteins within cancer cells that…
Molecular Profiling: Getting to Know Your Tumor
Dr. Johanna Bendell explains the value of molecular profiling. It can indicate which type of chemotherapy will be more successful on your tumor.
The ABCs of Genetic Testing
There are a number of different genetic mutations that can cause familial pancreatic cancer. This article explains some of the most common ones.
Luck, Grit, and Support
Joel Weiss had to travel from his home in Toronto to New York City to get the treatment he wanted for his pancreatic cancer.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Pancreatic Cancer Leads to a New Direction
After Sheila Sky Kasselman recovered from pancreatic cancer treatment, she became a pancreatic cancer activist, determined to help find more treatments.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
- 1
- 2
